An ex vivo platform that measures how your compound behaves in real blood-cancer cells — integrating drug sensitivity, combination synergy, flow cytometry, NGS, and machine-learning analytics into a single workflow.
Primary blood-cancer cells are notoriously fragile outside the body. ImpriMed's proprietary Optimum Media preserves the viability and stability of patient-derived cells after biopsy — where conventional media lose them within days.
That viability window is what enables quantitative, reproducible functional testing on real patient cells. It is difficult to replicate — and it is the technical foundation of everything below.
Individual dose-response curves, IC₅₀ / AUC / Eₘₐₓ tables, and cross-sample statistics.
Multi-drug combinations with quantitative synergy metrics (Bliss, Loewe, ZIP, HSA) and full dose-response data.
Gating strategies, population viability, and antigen expression — resolving response in the malignant population.
Targeted or full NGS — mutation summary, gene list, VAF, DEGs, and predicted impact.
Responder stratification, biomarker and clinical insights, and inclusion-criteria recommendations.
scRNA-seq (UMAP, pathway, cluster markers) and bulk RNA-seq / Methyl-seq integration.
* Every study is custom-designed for your candidates, controls, dose ranges, readouts, and statistical analysis.
An ML analytics layer scores synergy, classifies response patterns, extracts predictive biomarkers, and stratifies responders from non-responders — transforming multidimensional functional and genomic data into a sponsor-ready interpretation.
A scientist — not a sales desk — will scope a tailored study on primary patient cells.
